BR112016012123A8 - composto de triazolo-piridina - Google Patents
composto de triazolo-piridinaInfo
- Publication number
- BR112016012123A8 BR112016012123A8 BR112016012123A BR112016012123A BR112016012123A8 BR 112016012123 A8 BR112016012123 A8 BR 112016012123A8 BR 112016012123 A BR112016012123 A BR 112016012123A BR 112016012123 A BR112016012123 A BR 112016012123A BR 112016012123 A8 BR112016012123 A8 BR 112016012123A8
- Authority
- BR
- Brazil
- Prior art keywords
- pyridine compound
- group
- triazolo pyridine
- compounds
- triazolo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
- C07D249/18—Benzotriazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Abstract
a presente invenção refere-se a compostos da fórmula em que r1 é selecionado do grupo que consiste em h e ch3; r2 é selecionado do grupo que consiste em h e ch3; r3 é selecionado do grupo que consiste em h, c1-c3 alquila, o(ch2)3so2ch3, o(ch2)2och3, o(ch2)2c(ch3)2oh, cn, e ocf2; ou um sal farmaceuticamente aceitável deste, métodos de tratamento de diabetes, intermediários, e um processo para a preparação dos compostos da invenção.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361915774P | 2013-12-13 | 2013-12-13 | |
| PCT/US2014/068487 WO2015088868A1 (en) | 2013-12-13 | 2014-12-04 | A novel triazolo-pyridine compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016012123A8 true BR112016012123A8 (pt) | 2018-01-30 |
Family
ID=52144909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016012123A BR112016012123A8 (pt) | 2013-12-13 | 2014-12-04 | composto de triazolo-piridina |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9120793B2 (pt) |
| EP (1) | EP3080093B1 (pt) |
| JP (1) | JP6152227B2 (pt) |
| KR (1) | KR20160077207A (pt) |
| CN (1) | CN105814026B (pt) |
| AR (1) | AR098522A1 (pt) |
| AU (1) | AU2014364224B2 (pt) |
| BR (1) | BR112016012123A8 (pt) |
| CA (1) | CA2929317A1 (pt) |
| EA (1) | EA201690879A1 (pt) |
| ES (1) | ES2653522T3 (pt) |
| MX (1) | MX2016007567A (pt) |
| TW (1) | TW201609722A (pt) |
| WO (1) | WO2015088868A1 (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3092240B1 (en) | 2014-01-10 | 2018-12-05 | Eli Lilly and Company | Isopropyl triazolo pyridine compounds |
| EA201691071A1 (ru) * | 2014-01-10 | 2016-11-30 | Эли Лилли Энд Компани | Фенилтриазолопиридиновые соединения |
| US10106553B2 (en) | 2016-04-11 | 2018-10-23 | Janssen Pharmaceutica Nv | Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes |
| US10195178B2 (en) | 2016-04-11 | 2019-02-05 | Janssen Pharmaceutica Nv | GPR40 agonists in anti-diabetic drug combinations |
| CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
| CN112041311B (zh) | 2018-04-19 | 2023-10-03 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
| KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| IL291985A (en) | 2019-10-07 | 2022-06-01 | Kallyope Inc | gpr119 agonists |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| EP4172162A1 (en) | 2020-06-26 | 2023-05-03 | Kallyope, Inc. | Ampk activators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003277576A1 (en) | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| CA2527691C (en) | 2003-05-30 | 2013-01-22 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| WO2005066136A1 (en) * | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Bicyclic derivatives as ppar modulators |
| CN1946666A (zh) * | 2004-02-27 | 2007-04-11 | 埃姆艮股份有限公司 | 用于治疗代谢性疾病的化合物、药物组合物和方法 |
| US7572807B2 (en) * | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| CA2662242C (en) * | 2006-09-07 | 2012-06-12 | Amgen Inc. | Benzo-fused compounds for use in treating metabolic disorders |
| EP2310371B1 (fr) * | 2008-05-26 | 2013-05-15 | Genfit | Composés agonistes ppar, préparation et utilisations pour le traitement du diabète et/ou des dyslipidémies |
| US8530413B2 (en) * | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TWI692469B (zh) | 2012-11-09 | 2020-05-01 | 南韓商Ｌｇ化學股份有限公司 | Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物 |
-
2014
- 2014-11-24 TW TW103140672A patent/TW201609722A/zh unknown
- 2014-11-25 AR ARP140104404A patent/AR098522A1/es unknown
- 2014-12-04 CN CN201480068007.5A patent/CN105814026B/zh active Active
- 2014-12-04 JP JP2016537995A patent/JP6152227B2/ja not_active Expired - Fee Related
- 2014-12-04 ES ES14816539.2T patent/ES2653522T3/es active Active
- 2014-12-04 MX MX2016007567A patent/MX2016007567A/es unknown
- 2014-12-04 BR BR112016012123A patent/BR112016012123A8/pt not_active IP Right Cessation
- 2014-12-04 US US14/559,956 patent/US9120793B2/en active Active
- 2014-12-04 EP EP14816539.2A patent/EP3080093B1/en active Active
- 2014-12-04 KR KR1020167015181A patent/KR20160077207A/ko not_active Application Discontinuation
- 2014-12-04 EA EA201690879A patent/EA201690879A1/ru unknown
- 2014-12-04 AU AU2014364224A patent/AU2014364224B2/en not_active Expired - Fee Related
- 2014-12-04 WO PCT/US2014/068487 patent/WO2015088868A1/en active Application Filing
- 2014-12-04 CA CA2929317A patent/CA2929317A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US9120793B2 (en) | 2015-09-01 |
| MX2016007567A (es) | 2017-01-06 |
| KR20160077207A (ko) | 2016-07-01 |
| JP2016539984A (ja) | 2016-12-22 |
| AU2014364224B2 (en) | 2017-02-16 |
| CA2929317A1 (en) | 2015-06-18 |
| WO2015088868A1 (en) | 2015-06-18 |
| AR098522A1 (es) | 2016-06-01 |
| EP3080093B1 (en) | 2017-10-04 |
| US20150166535A1 (en) | 2015-06-18 |
| ES2653522T3 (es) | 2018-02-07 |
| CN105814026B (zh) | 2018-08-10 |
| JP6152227B2 (ja) | 2017-06-21 |
| CN105814026A (zh) | 2016-07-27 |
| AU2014364224A1 (en) | 2016-05-19 |
| EP3080093A1 (en) | 2016-10-19 |
| EA201690879A1 (ru) | 2016-10-31 |
| TW201609722A (zh) | 2016-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016012123A8 (pt) | composto de triazolo-piridina | |
| CY1121549T1 (el) | Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων | |
| PH12017501016B1 (en) | Triazolopyrimidine compounds and uses thereof | |
| CR20160220A (es) | PIRROLO [1,2-f][1,2,4] TRIAZINAS ÚTILES PARA TRATAR INFECCIONES POR EL VIRUS SINCITIAL RESPIRATORIO | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| EA201690094A1 (ru) | Ингибиторы syk | |
| BR112016014020A8 (pt) | moduladores de tetra-hidropiridopirazinas de gpr6. | |
| BR112016012469A2 (pt) | Isopropil triazolo piridina, seus usos, seu processo de preparação e seus intermediários, composição farmacêutica | |
| PE20160523A1 (es) | Derivados de arilo o heteroarilo como inhibidores de moleculas pequenas de fibrosis | |
| AR098912A1 (es) | Inhibidores de syk | |
| BR112016013874A2 (pt) | Fenil-triazolo-piridina, seus usos, seus processo de produção e seus intermediários, e composição farmacêutica | |
| CU20150129A7 (es) | Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos | |
| PH12016501047A1 (en) | Ester derivatives of androgen receptor modulators and methods for their use | |
| BR112015008037A2 (pt) | compostos, processo para a preparação de um composto, composição farmacêutica, utilização do composto, método para o tratamento do câncer e invenção | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| GT201400167A (es) | Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 | |
| EA201490754A1 (ru) | Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора | |
| PE20190979A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| DOP2014000177A (es) | Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2 | |
| BR112016029510A2 (pt) | métodos para a preparação de um composto, e, composto intermediário. | |
| MX2016004967A (es) | Tratamiento para cancer pancreatico. | |
| EA201600323A1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| BR112016011778A8 (pt) | pirazol fluorofenila, seus usos, e composição farmacêutica | |
| BR112016006979A2 (pt) | processo industrial para a síntese de acetato de ulipristal e seu análogo de 4'-acetila | |
| BR112016007646A2 (pt) | forma cristalina anidra de cabazitaxel, uso da forma cristalina anidra de cabazitaxel, composição farmacêutica e processo para o preparo forma cristalina anidra de cabazitaxe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |